No Need To Reconsider Immunity At PTAB, Fed. Circ. Hears
Mylan Pharmaceuticals Inc. and other generic-drug companies challenging Allergan PLC patents for dry-eye medication Restasis urged the full Federal Circuit on Tuesday not to reconsider an earlier decision that tribal sovereign...To view the full article, register now.
Already a subscriber? Click here to view full article